The multi-CDK inhibitor dinaciclib reverses bromo- and extra-terminal domain (BET) inhibitor resistance in acute myeloid leukemia via inhibition of Wnt/β-catenin signaling.
Saved in:
| Title: | The multi-CDK inhibitor dinaciclib reverses bromo- and extra-terminal domain (BET) inhibitor resistance in acute myeloid leukemia via inhibition of Wnt/β-catenin signaling. |
|---|---|
| Authors: | Marr, Alexander R.1 (AUTHOR), Halpin, Madeline1 (AUTHOR), Corbin, Dominique L.1 (AUTHOR), Asemelash, Yerdanos1 (AUTHOR), Sher, Steven1 (AUTHOR), Gordon, Britten K.1 (AUTHOR), Whipp, Ethan C.1 (AUTHOR), Mitchell, Shaneice2 (AUTHOR), Harrington, Bonnie K.3 (AUTHOR), Orwick, Shelley1 (AUTHOR), Benrashid, Samon1 (AUTHOR), Goettl, Virginia M.1 (AUTHOR), Yildiz, Vedat4 (AUTHOR), Mitchell, Andrew D.1 (AUTHOR), Cahn, Olivia1 (AUTHOR), Mims, Alice S.1 (AUTHOR), Larkin, Karilyn T. M.1 (AUTHOR), Long, Meixao1 (AUTHOR), Blachly, James1,5 (AUTHOR), Woyach, Jennifer A.1,5 (AUTHOR) |
| Source: | Experimental Hematology & Oncology. 3/4/2024, Vol. 13 Issue 1, p1-21. 21p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
